Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Live attenuated rotavirus vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Live attenuated rotavirus vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Subjects with parents/guardians who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study. * Males or females between, and including, 6 and 12 weeks (42 - 90 days) of age at the time of the first vaccination. * Writ...
Live attenuated rotavirus vaccine is an investigational vaccine being studied for the prophylaxis of rotavirus gastroenteritis, a condition caused by rotavirus infections. It is intended to prevent rotavirus-related illness in susceptible populations, with clinical development focused on assessing its immunogenicity and safety.
Live attenuated rotavirus vaccine is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research to evaluate the vaccine's potential for preventing rotavirus gastroenteritis.
Live attenuated rotavirus vaccine is in Phase 2 clinical development. It is an investigational product and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the vaccine remains under evaluation for its safety and immunogenicity profile.
Live attenuated rotavirus vaccine has one completed Phase 2 clinical trial registered as NCT00137930. The study, titled 'Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis,' enrolled 250 participants in Finland and evaluated the vaccine's safety and immunogenicity.
Live attenuated rotavirus vaccine is also known as Human Rotavirus (HRV) vaccine. The clinical trial NCT00137930 refers to it as the HRV vaccine, and it is being studied for the prophylaxis of rotavirus gastroenteritis. The vaccine is an investigational product in Phase 2 development.